CEL-SCI Corporation Releases Letter to Sh... (ale following approval. We have also de...)

CEL-SCI Corporation Releases Letter to Shareholders

Date:2/20/2009

ale following approval. We have also designed the facility to be used as a contract manufacturing facility during those times (e.g., during certain times in the Phase III study) when we will not be producing Multikine. This lucrative business could quickly become a multi-million dollar revenue generator for CEL-SCI.

We presented very promising data on a new rheumatoid arthritis vaccine discovered by CEL-SCI scientists. The data presented was as good as that achieved with Enbrel, a leading treatment for rheumatoid arthritis.

We started planning and pricing our global clinical trial designed to lead to marketing approval for Multikine. The recent strength of the dollar will reduce our Phase III study costs by several million dollars.

While we are pleased by these accomplishments, we also recognize that there are major challenges due to the severe financial downturn. This downturn has affected all of us, but we have taken immediate action. We very quickly reduced our expenditures and expanded our discussions with various pharmaceutical companies for a world-wide Multikine partnership. Things are very difficult all around for most companies, but we are seeing new strength in the bigger biotechnology names. This will hopefully trickle down to the smaller ones like us as well. The huge buyouts in the industry, Pfizer buying Wyeth and Roche trying to buy Genentech, will add over $100 billion in liquidity to the industry, and that too should help us down the road.

Let me share with you how we at CEL-SCI are dealing with and planning for recovery from this financial downturn. In our opinion, during such a difficult time as this you cannot rely on one strategy alone. Therefore we are pursuing the following multi-pronged strategy. To
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
2. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
3. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
4. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
5. CEL-SCI Corporation Reports First Quarter Financial Results
6. CEL-SCI Corporation Announces 2007 Financial Results
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
8. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
9. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum

Post Your Comments:

(Date:5/18/2013)... 2013 The Open Paradigm Project, in ... Occupy Psychiatry , and leading organizations in the ... social media campaign showcasing video testimonials by individuals ... focuses on pathology and illness rather than wellness ... Psychiatric Association,s (APA) rollout of its latest revision ...

(Date:5/17/2013)... -- Medical devices are any medical items that are ... of their different mechanisms, actions and regulatory requirements, medical ... drug trails due to their unique clinical practices. Currently, ... both safety and efficacy (which is left to the ... as the SFDA) evaluate MDs for both safety and ...

(Date:5/17/2013)... , May 17, 2013 Orexigen® Therapeutics, Inc. (Nasdaq: ... a company overview at the UBS Global Healthcare Conference in ... for Wednesday, May 22 nd at 11 a.m. Eastern ... of the presentation, please visit the Investor Relations section of ... will be available for 14 days after the event. ...

Breaking Medicine Technology:New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2 New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3 Statistical Challenges in Medical Device Trail Evaluation 2

[0] New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses [0] Statistical Challenges in Medical Device Trail Evaluation [0] Orexigen Therapeutics to Present at the UBS Global Healthcare Conference

... ADD NEW CENTERS AND TO ... INCREASE AWARENESS AMONG CARDIOLOGISTS, PLEASANTON, Calif., April 21 ... device-based mechanical,circulatory support therapies to save, support and restore failing ... PMA (PreMarket,Approval) application, allowing the use of its HeartMate II ...

... EDISON, N.J., April 21 Nostrum, a ... today that it has,successfully completed its early, ... protein currently known as SMRX11. Nostrum,s,Symmetrix subsidiary, ... drug under Nostrum,s license from the Institute ...

Cached Medicine Technology:Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 2 Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 3 Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 4 Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 5 Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein 2

Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein

(Date:5/20/2013)... (PRWEB) May 20, 2013 iGearUnlimited.com asked schools' ... iPad case for students. The answers didn't surprise anyone: , ... daily use and abuse, 2. Not too bulky – need ... backpack, 3. Built-in kick-stand that works in both vertical and ... as a trackable barcodes on each case, 5. Customizable – ...

(Date:5/20/2013)... Atlanta, GA (PRWEB) May 20, 2013 ... opening of their newest office on Briarcliff Road in ... urgent care facility includes Dr. Fidias E. De ... massage therapists who will provide extensive medical services, occupational ... of the greater Atlanta metropolitan area. They also offer ...

(Date:5/20/2013)... OH (PRWEB) May 20, 2013 The ... experienced medical device law firm, report that two important ... coming months in state and federal litigations established for ... June 11th, the first C.R. Bard bellwether trial will ... Southern District of West Virginia. (In re: C.R. ...

(Date:5/19/2013)... NY (PRWEB) May 20, 2013 Alonso ... they are representing a New York woman in a ... with the National Football League (NFL). According to an ... Petitioner is seeking a declaration of paternity, order of support ... of her son with Mr. Walker. (Docket No. P-18821-13) ...

(Date:5/19/2013)... measure of the heterogeneity the variety of genetic mutations ... outcomes of patients with the most common type of head ... the journal Cancer , investigators at Massachusetts General Hospital ... measure was a better predictor of survival than most traditional ... cell carcinoma of the head and neck. , ...

Breaking Medicine News(10 mins):Health News:New Rugged iPad Case for Bretford Charging Cart Saves the Day for School Deployments 2 Health News:New Rugged iPad Case for Bretford Charging Cart Saves the Day for School Deployments 3 Health News:Healing Heart Urgent Care Opens New Office In Atlanta 2 Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 2 Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 3 Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 4 Health News:New York Woman in Paternity Petition Against Former NFL Running Back, Herschel Walker, Alonso Krangle LLP Representing Petitioner 2 Health News:New York Woman in Paternity Petition Against Former NFL Running Back, Herschel Walker, Alonso Krangle LLP Representing Petitioner 3 Health News:Genetic diversity within tumors predicts outcome in head and neck cancer 2 Health News:Genetic diversity within tumors predicts outcome in head and neck cancer 3

[0] New Rugged iPad Case for Bretford Charging Cart Saves the Day for School Deployments [0] Healing Heart Urgent Care Opens New Office In Atlanta [0] Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials [0] New York Woman in Paternity Petition Against Former NFL Running Back, Herschel Walker, Alonso Krangle LLP Representing Petitioner [0] Genetic diversity within tumors predicts outcome in head and neck cancer

... 91% Increase in Earnings for First Half of 2008 ... Metropolitan,Health Networks, Inc. (Amex: MDF ), a ... results for the six months,and quarter ended June 30, ... that in the three months ended,June 30, 2008, the ...

... /Xinhua-PRNewswire/ -- Simcere Pharmaceutical,Group (NYSE: SCR ), a ... of the patented anti-cancer biotech,product Endu in China, today ... 2008., Highlights -- Total revenue increased ... second quarter, representing a 30.4% year-over-year growth;, ...

... Year-over-Year to $10.7 Million Backlog Reaches $72 ... Million ... to Market Recently-introduced Odyssey System Building Strong Market Momentum, ST. ... second quarter ended June,30, 2008. Revenue for the recent second quarter increased 36% ...

... goes for gold and aims to give back to Mercy Ships ... ... Laser Champion and one of Britain,s greatest medal hopes at the Beijing ... charity Mercy Ships which provides free medical care to the people of ...

... major website re-design, aimed specifically toward potential clients, with improved ... ... New York, NY (PRWEB) August 5, 2008 -- ... re-design, aimed specifically toward potential clients, with improved navigability, clear ...

... esignature, Princor representatives now benefit from a more efficient account ... ... Ontario, CA (PRWEB) August 5, 2008 -- Interlink Electronics, Inc. ... Corporation, a member of the Principal Financial Group®. The Princor® ...

Metropolitan Health Networks Reports 2008 Second Quarter Results Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results Stereotaxis Reports Record Second Quarter Revenue Olympic Sailing Hopeful Backs Hospital Ship Charity Re-Designed Legal Website Includes Blog Interlink and LaserApp Partnership Provides eSignature-Ready Forms to Princor Financial Services

The Easy Wrap Apron is now available with an attached Thyroid Collar. The Thyroid Collar is held on with velcro so it adjusts to fully protect the neck. This Apron with Collar is available in 5mm lea...

... system is a long term, ... clinically proven design. Available in ... correct cruciate retaining configurations. In ... of identification keeps the user ...

... The Genesis II® Total Knee System ... Now, far more is possible with less ... options, while fully addressing both clinical and ... meet these design goals, giving surgeons creative ...

Cementless hip system...

Medicine Products:

Easy Wrap Apron w/Collar: Lead Free Proven™ Posterior Stabilized Knee System Genesis II® Total Knee System Primaloc™ Cementless